Testing effectiveness (Phase 2)WithdrawnNCT05618691
What this trial is testing
GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
Who this might be right for
Intermittent ClaudicationPeripheral Artery Disease
Zhejiang Genfleet Therapeutics Co., Ltd.